Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Exemestane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 known ✓ | P11511 | 18/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Exemestane SCHEMBL178041 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL172893 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL19452231 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL6730580 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL13794245 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL6215 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL1781618 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL172860 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| Exemestane SCHEMBL21698489 | 1.00 | CYP19A1 (1.00) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 | |
| SCHEMBL13301017 | 0.92 | CYP19A1 (0.84) | CYP19A1KDM4EALDH1A1ABCB11NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2065038-A1 | New therapeutic approaches for treating Charcot-Marie-Tooth disease | Pharnext (FR) | 2009-06-03 | — | — | EP | claimed |
| US-10071953-B2 | Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-09-11 | — | — | US | disclosed |
| US-20160159731-A1 | Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof | UNIV PENNSYLVANIA (US) | 2016-06-09 | — | — | US | disclosed |
| US-9271961-B2 | Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-03-01 | — | — | US | disclosed |
| US-20140107085-A1 | Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-04-17 | — | — | US | disclosed |
| WO-2011082458-A1 | ADJUVANT IMMUNOTHERAPY FOR THE PREVENTIVE, CURATIVE OR PALLIATIVE TREATMENT OF CHRONIC SYSTEMIC DISEASES SUCH AS CANCER, OF CLINICAL MANIFESTATIONS ASSOCIATED WITH THESE DISEASES, SUCH AS CACHEXIA, AND REMEDYING ADVERSE EFFECTS OF DRUGS AND TREATMENTS, SUCH AS IMMUNODEPRESSION, NEUTROPENIA AND LYMPHOCYTOPENIA, COMPRISING THE ASSOCIATION OR COMBINATION OF A SPECIALLY SELECTED BIOLOGICAL RESPONSE MODIFIER AND OTHER ANTINEOPLASTIC COMPOUNDS AND/OR OTHER TREATMENTS | NUNES LSEU DA SILVA (BR) | 2011-07-14 | — | — | WO | disclosed |
| US-20100069340-A1 | PHARMACEUTICAL COMPOSITIONS OF AN SRC KINASE INHIBITOR AND AN AROMATASE INHIBITOR | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
| EP-2065038-A1 | New therapeutic approaches for treating Charcot-Marie-Tooth disease | Pharnext (FR) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10071953-B2 | Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof | AR, AKR1C3, AKR1C2 | CYP19A1 7/4885KDM4E 1406/4885ALDH1A1 230/4885 |
| US-20140107085-A1 | Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof | AR, AKR1C3, AKR1C2 | CYP19A1 7/4885KDM4E 1406/4885ALDH1A1 230/4885 |
| US-20160159731-A1 | Bifunctional AKR1C3 Inhibitors/Androgen Receptor Modulators and Methods of Use Thereof | AR, AKR1C3, AKR1C2 | CYP19A1 7/4885KDM4E 1406/4885ALDH1A1 230/4885 |
| US-20100069340-A1 | PHARMACEUTICAL COMPOSITIONS OF AN SRC KINASE INHIBITOR AND AN AROMATASE INHIBITOR | CYP19A1, SRC, CYP17A1 | CYP19A1 1/4885KDM4E 738/4885ALDH1A1 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.